Biogen Idec, Inc. (Massachusetts), Elan Corporation PLC: CHMP Recommends Updating TYSABRI Labeling with anti-JC Virus Antibody Status as a Third Factor to Further Stratify Risk of PML

WESTON, Mass. & DUBLIN--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for inclusion of an additional risk factor, anti-JC virus (JCV) antibody status, to the product label for TYSABRI® (natalizumab) in the European Union (EU). The CHMP has also adopted a positive opinion for the five year renewal of the Marketing Authorisation for TYSABRI.